Lexeo Therapeutics Files 8-K
Ticker: LXEO · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
TL;DR
Lexeo Therapeutics filed a routine 8-K on 4/7/25. No major news.
AI Summary
Lexeo Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting on other events and financial statements. The filing does not contain specific details about new material events, significant financial changes, or executive actions beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a standard disclosure for Lexeo Therapeutics, Inc., providing updates on corporate events and financial information as required by the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no indication of new risks or significant negative developments.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- April 07, 2025 (date) — Date of earliest event reported
- 212 547-9879 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Lexeo Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of April 7, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 07, 2025.
What is Lexeo Therapeutics, Inc.'s principal executive office address?
Lexeo Therapeutics, Inc.'s principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York 10010.
What is the SIC code for Lexeo Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Lexeo Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the company's telephone number as listed in the filing?
The company's telephone number, including area code, is (212) 547-9879.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding Lexeo Therapeutics, Inc. (LXEO).